Mineralys Therapeutics’ $150 Million Registered Direct Offering

Cleary Gottlieb represented the underwriters, BofA Securities Inc., Goldman Sachs & Co. LLC, and Evercore Group LLC, in Mineralys Therapeutics Inc.’s (Mineralys) $150 million registered direct offering.

The offering, which was comprised of the issuance of 5.66 million shares of Mineralys’ common stock, priced on June 3, 2026, and closed on June 4, 2026.

Mineralys is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as CKD, OSA, and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific.

For more information, please see the press release.

The Cleary capital markets team included partners Ilir Mujalovic, Harald Halbhuber, and Synne Chapman; counsel Elizabeth Chang; and associates Peter Simon, Marc Chien, and Julian Vleeschhouwer. Partner Matthew Brigham and associates Nathaniel Pribil and Michael Hughes advised on tax matters. Partner Marcela Robledo and associate Christine D’Alessandro advised on intellectual property matters, with support from law clerk Gabriela Landolfo.